• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20062 / SuperGen Announces Interim Results of Orathecin™ Combination Trial in P...

SuperGen Announces Interim Results of Orathecin™ Combination Trial in Pancreatic Cancer

26 April 2006/in 2006, News

SuperGen Announces Interim Results of Orathecin™ Combination Trial in Pancreatic Cancer

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2006-04-26 13:59:202016-11-28 13:59:42SuperGen Announces Interim Results of Orathecin™ Combination Trial in Pancreatic Cancer

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Therapeutics announces IND approval for novel cancer drug AT9283 Link to: Astex Therapeutics announces IND approval for novel cancer drug AT9283 Astex Therapeutics announces IND approval for novel cancer drug AT9283 Link to: U.S. FDA Approves Dacogen™ (Decitabine) For Injection Link to: U.S. FDA Approves Dacogen™ (Decitabine) For Injection U.S. FDA Approves Dacogen™ (Decitabine) For Injection
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok